{"id":542603,"date":"2021-05-10T23:00:01","date_gmt":"2021-05-10T23:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542603"},"modified":"2021-05-10T23:00:01","modified_gmt":"2021-05-10T23:00:01","slug":"neutropenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-spectrum-pharmaceuticals-cellerant-therapeutics-x4-pharmaceuticals-tanvex-biopharma-enzychem-lifesciences","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neutropenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-spectrum-pharmaceuticals-cellerant-therapeutics-x4-pharmaceuticals-tanvex-biopharma-enzychem-lifesciences_542603.html","title":{"rendered":"Neutropenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Spectrum Pharmaceuticals, Cellerant Therapeutics, X4 Pharmaceuticals, Tanvex Biopharma, Enzychem Lifesciences"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1620617828.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Neutropenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Spectrum Pharmaceuticals, Cellerant Therapeutics, X4 Pharmaceuticals, Tanvex Biopharma, Enzychem Lifesciences\" src=\"https:\/\/www.abnewswire.com\/uploads\/1620617828.jpeg\" alt=\"Neutropenia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Spectrum Pharmaceuticals, Cellerant Therapeutics, X4 Pharmaceuticals, Tanvex Biopharma, Enzychem Lifesciences\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Neutropenia Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Neutropenia<\/strong> is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms can range from mild to severe. The lower the level of neutrophils, the more intense the symptoms. Typical symptoms include: fever, pneumonia, sinus infections, otitis media (ear infection), gingivitis (gum inflammation), omphalitis (navel infection) and skin abscesses. Severe congenital neutropenia can have serious symptoms. The symptoms often include bacterial infections.&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,&nbsp;<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neutropenia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Neutropenia Pipeline<\/a> Insight, 2021,&rdquo;<\/strong>&nbsp;report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Neutropenia Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Tanvex Biopharma<\/li>\n<li>Enzychem Lifesciences<\/li>\n<li>BeyondSpring Pharmaceuticals<\/li>\n<li>Mabwell (Shanghai) Bioscience<\/li>\n<li>Emendo biotherapeutics<\/li>\n<li>Spectrum Pharmaceuticals<\/li>\n<li>Cellerant Therapeutics<\/li>\n<li>X4 Pharmaceuticals<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Neutropenia report covers around 30+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III and<\/li>\n<li>Mid-stage products (Phase II and<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/neutropenia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Neutropenia Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Plinabulin<\/li>\n<li>Romyelocel-L<\/li>\n<li>EC-18<\/li>\n<li>TX-04<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Current Neutropenia Treatment Scenario and Neutropenia Emerging Therapies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>How many companies are developing Neutropenia drugs?<\/li>\n<li>How many Neutropenia drugs are developed by each company?<\/li>\n<li>How many emerging drugs are in mid-stage, and late-stage of development for Neutropenia?<\/li>\n<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?<\/li>\n<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?<\/li>\n<li>What are the clinical studies going on for Neutropenia and their status?<\/li>\n<li>What are the key designations that have been granted to the emerging drugs?<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Neutropenia : Overview<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Neutropenia &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">Neutropenia&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Late Stage Products (Phase III)&nbsp;<\/p>\n<p style=\"text-align: justify;\">Romyelocel-L: Cellerant Therapeutics<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase II)<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">EC-18: Enzychem Lifesciences<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Early Stage Products (Phase I)&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">TX-04: Tanvex Biopharma<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<ul style=\"text-align: justify;\">\n<li>Comparative Analysis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Neutropenia&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">Neutropenia&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">Neutropenia- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Neutropenia- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Neutropenia- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Neutropenia&nbsp;Analyst Views<\/p>\n<p style=\"text-align: justify;\">Neutropenia&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/neutropenia-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=neutropenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-spectrum-pharmaceuticals-cellerant-therapeutics-x4-pharmaceuticals-tanvex-biopharma-enzychem-lifesciences\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/neutropenia-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/neutropenia-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/neutropenia-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=neutropenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-spectrum-pharmaceuticals-cellerant-therapeutics-x4-pharmaceuticals-tanvex-biopharma-enzychem-lifesciences\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Neutropenia Pipeline Neutropenia is a blood condition characterized by low levels of neutrophils, which are white blood cells that protect your body from infections. There are four types of neutropenia: Congenital neutropenia, cyclic neutropenia, autoimmune neutropenia, Idiopathic neutropenia. Neutropenia symptoms &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/neutropenia-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-spectrum-pharmaceuticals-cellerant-therapeutics-x4-pharmaceuticals-tanvex-biopharma-enzychem-lifesciences_542603.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-542603","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542603"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542603\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}